Comparative Efficacy of <scp>PD</scp>‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage <scp>II</scp>–<scp>IIIa NSCLC</scp>: A Real‐World Retrospective Study
All treatment regimens elicited substantial pathological responses and exhibited acceptable safety profiles. Pembrolizumab and tislelizumab were associated with better OS and lower toxicity, supporting their preferential use in neoadjuvant therapy for resectable NSCLC.
Authors
- Xiaoxuan Sun
- Yulong Chen (ORCID: https://orcid.org/0000-0003-4754-3056)
- Bo Yan (ORCID: https://orcid.org/0000-0003-1391-5683)
- Ran Zhang (ORCID: https://orcid.org/0000-0002-4142-805X)
- Sheng Yan (ORCID: https://orcid.org/0000-0001-7795-8725)
- Yanjun Su (ORCID: https://orcid.org/0009-0002-0725-1243)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1111/1759-7714.70123
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00